

Terry Cheuk-Fung Yip

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3266571/publications.pdf>

Version: 2024-02-01

128
papers

3,691
citations

212478

28
h-index

175968

55
g-index

129
all docs

129
docs citations

129
times ranked

4036
citing authors

#	ARTICLE	IF	CITATIONS
1	Risks of post-colonoscopy polypectomy bleeding and thromboembolism with warfarin and direct oral anticoagulants: a population-based analysis. <i>Gut</i> , 2022, 71, 100-110.	6.1	22
2	Reply. <i>Hepatology</i> , 2022, 75, 1051-1052.	3.6	0
3	Methodological challenges of performing meta-analyses to compare the risk of hepatocellular carcinoma between chronic hepatitis B treatments. <i>Journal of Hepatology</i> , 2022, 76, 186-194.	1.8	14
4	Asian perspective on NAFLD-associated HCC. <i>Journal of Hepatology</i> , 2022, 76, 726-734.	1.8	59
5	Association of genetic variations with NAFLD in lean individuals. <i>Liver International</i> , 2022, 42, 149-160.	1.9	33
6	U-shaped relationship between urea level and hepatic decompensation in chronic liver diseases. <i>Clinical and Molecular Hepatology</i> , 2022, 28, 77-90.	4.5	12
7	Weakly Supervised Liver Tumor Segmentation Using Couinaud Segment Annotation. <i>IEEE Transactions on Medical Imaging</i> , 2022, 41, 1138-1149.	5.4	8
8	Novel machine learning models outperform risk scores in predicting hepatocellular carcinoma in patients with chronic viral hepatitis. <i>JHEP Reports</i> , 2022, 4, 100441.	2.6	12
9	Angiotensin-converting enzyme inhibitors prevent liver-related events in nonalcoholic fatty liver disease. <i>Hepatology</i> , 2022, 76, 469-482.	3.6	41
10	Use of Proton-Pump Inhibitor Is Not Associated with Adverse Clinical Outcomes in COVID-19 Patients: A Territory-Wide Cohort Study. <i>GastroHep</i> , 2022, 2022, 1-13.	0.3	0
11	Letter: systematic review with meta-analysis on the impact of functional cure on clinical outcomes in patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 616-617.	1.9	1
12	Reply. <i>Hepatology</i> , 2022, 76, E34-E35.	3.6	0
13	Management of hepatitis B virus reactivation due to treatment of COVID-19. <i>Hepatology International</i> , 2022, 16, 257-268.	1.9	17
14	Risk of liver-related events by age and diabetes duration in patients with diabetes and nonalcoholic fatty liver disease. <i>Hepatology</i> , 2022, 76, 1409-1422.	3.6	24
15	No increased risk of flare in ulcerative colitis patients in corticosteroid-free remission after stopping 5-aminosalicylic acid: A territory-wide population-based study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 1284-1289.	1.4	4
16	Effectiveness of prophylactic clipping in preventing postpolypectomy bleeding in oral anticoagulant users: a propensity-score analysis. <i>Gastrointestinal Endoscopy</i> , 2022, 96, 530-542.e1.	0.5	3
17	Tenofovir alafenamide is associated with improved alanine aminotransferase and renal safety compared to tenofovir disoproxil fumarate. <i>Journal of Medical Virology</i> , 2022, 94, 4440-4448.	2.5	5
18	Hepatic Decompensation in Cirrhotic Patients Receiving Antiviral Therapy for Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1950-1958.e7.	2.4	18

#	ARTICLE	IF	CITATIONS
19	Reply to Hoffmann and Wolf. <i>Clinical Infectious Diseases</i> , 2021, 73, e1782-e1783.	2.9	0
20	Explainable Uncertainty-Aware Convolutional Recurrent Neural Network for Irregular Medical Time Series. <i>IEEE Transactions on Neural Networks and Learning Systems</i> , 2021, 32, 4665-4679.	7.2	17
21	Liver injury is independently associated with adverse clinical outcomes in patients with COVID-19. <i>Gut</i> , 2021, 70, 733-742.	6.1	121
22	Predictors of the start of declining eGFR in patients with systemic lupus erythematosus. <i>Lupus</i> , 2021, 30, 15-24.	0.8	4
23	Biochemical follow-up of nonfunctioning benign thyroid nodules. <i>Clinical Endocrinology</i> , 2021, 94, 322-329.	1.2	1
24	Significantly Lower Case-fatality Ratio of Coronavirus Disease 2019 (COVID-19) than Severe Acute Respiratory Syndrome (SARS) in Hong Kong—A Territory-Wide Cohort Study. <i>Clinical Infectious Diseases</i> , 2021, 72, e466-e475.	2.9	26
25	Negligible HCC risk during stringently defined untreated immune-tolerant phase of chronic hepatitis B. <i>European Journal of Internal Medicine</i> , 2021, 84, 68-73.	1.0	12
26	Epidemiology and Natural History of Elderly-onset Inflammatory Bowel Disease: Results From a Territory-wide Hong Kong IBD Registry. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 401-408.	0.6	28
27	Hepatitis Flare During Immunotherapy in Patients With Current or Past Hepatitis B Virus Infection. <i>American Journal of Gastroenterology</i> , 2021, 116, 1274-1283.	0.2	37
28	Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. <i>Gut</i> , 2021, 70, 698-706.	6.1	818
29	Risks of AKI and Major Adverse Clinical Outcomes in Patients with Severe Acute Respiratory Syndrome or Coronavirus Disease 2019. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 961-971.	3.0	16
30	Clinical Spectrum and Renal Outcome of Cryoglobulinemia in Hong Kong. <i>Kidney360</i> , 2021, 2, 721-728.	0.9	0
31	Aspirin Reduces the Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Receiving Oral Nucleos(t)ide Analog. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00324.	1.3	20
32	Colonoscopy and Risk of Colorectal Cancer in Patients With Nonalcoholic Fatty Liver Disease: A Retrospective Territory-Wide Cohort Study. <i>Hepatology Communications</i> , 2021, 5, 1212-1223.	2.0	9
33	Neurological diseases and risk of mortality in patients with COVID-19 and SARS: a territory-wide study in Hong Kong. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1356-1358.	0.9	2
34	Negligible risk of hepatocellular carcinoma in chronic hepatitis B patients in immune-tolerant phase: Myth or fact. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 273-277.	4.5	6
35	SARS-CoV-2 Viral Persistence Based on Cycle Threshold Value and Liver Injury in Patients With COVID-19. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab205.	0.4	10
36	Liver—heart connection in diabetes mellitus. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1385-1386.	1.4	0

#	ARTICLE	IF	CITATIONS
37	Current and Past Infections of HBV Do Not Increase Mortality in Patients With COVID-19. <i>Hepatology</i> , 2021, 74, 1750-1765.	3.6	41
38	Drug-induced liver injury in Australia, 2009-2020: the increasing proportion of non-paracetamol cases linked with herbal and dietary supplements. <i>Medical Journal of Australia</i> , 2021, 215, 261-268.	0.8	18
39	Serum fibrosis index-based risk score predicts hepatocellular carcinoma in untreated patients with chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 499-509.	4.5	14
40	Sodium-glucose co-transporter 2 inhibitors reduce hepatic events in diabetic patients with chronic hepatitis B. <i>GastroHep</i> , 2021, 3, 261-269.	0.3	1
41	Secular trend of treatment uptake in patients with chronic hepatitis B: A territory-wide study of 135,395 patients from 2000 to 2017. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 3487-3499.	1.4	8
42	Editorial: central obesity is a risk factor for hepatocellular carcinoma in Asian patients with chronic hepatitis B on anti-viral therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 722-723.	1.9	4
43	Differential Impacts of Multimorbidity on COVID-19 Severity across the Socioeconomic Ladder in Hong Kong: A Syndemic Perspective. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 8168.	1.2	15
44	Predictors of Severe COVID-19 in Patients With Diabetes: A Multicenter Review. <i>Endocrine Practice</i> , 2021, 27, 842-849.	1.1	10
45	Association of metformin use on metabolic acidosis in diabetic patients with chronic hepatitis B-related cirrhosis and renal impairment. <i>Health Science Reports</i> , 2021, 4, e352.	0.6	1
46	Timing of endoscopy for acute upper gastrointestinal bleeding: a territory-wide cohort study. <i>Gut</i> , 2021, , gutjnl-2020-323054.	6.1	13
47	IDDF2021-ABS-0122-...No association between proton-pump inhibitor use and adverse clinical outcomes of COVID-19: a territory-wide cohort study of 8,675 patients. , 2021, , .		0
48	IDDF2021-ABS-0137-...The aMAP score predicts risk of hepatocellular carcinoma development in patients with alcohol-related cirrhosis. , 2021, , .		0
49	Importance-aware personalized learning for early risk prediction using static and dynamic health data. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2021, 28, 713-726.	2.2	6
50	Alanine Aminotransferase Level: The Road to Normal in 2021. <i>Hepatology Communications</i> , 2021, 5, 1807-1809.	2.0	3
51	Glucose-lowering drugs and outcome from COVID-19 among patients with type 2 diabetes mellitus: a population-wide analysis in Hong Kong. <i>BMJ Open</i> , 2021, 11, e052310.	0.8	17
52	Similarly low risk of hepatocellular carcinoma after either spontaneous or nucleos(t)ide analogue-induced hepatitis B surface antigen loss. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 321-331.	1.9	23
53	An Aging Population of Chronic Hepatitis B With Increasing Comorbidities: A Territory-Wide Study From 2000 to 2017. <i>Hepatology</i> , 2020, 71, 444-455.	3.6	52
54	Tenofovir Is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China. <i>Gastroenterology</i> , 2020, 158, 215-225.e6.	0.6	156

#	ARTICLE	IF	CITATIONS
55	How Do We Determine Whether a Functional Cure for HBV Infection Has Been Achieved?. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 548-550.	2.4	18
56	Risk of hepatitis B surface antigen seroreversion after corticosteroid treatment in patients with previous hepatitis B virus exposure. <i>Journal of Hepatology</i> , 2020, 72, 57-66.	1.8	54
57	Development and validation of a model for hepatitis B e antigen seroconversion in entecavirã-treated patients with chronic hepatitis B. <i>Journal of Medical Virology</i> , 2020, 92, 1206-1213.	2.5	5
58	The safety of stopping nucleos(t)ide analogue treatment in patients with HBsAgã-negative chronic hepatitis B. <i>Liver International</i> , 2020, 40, 549-557.	1.9	11
59	Reassessing the accuracy of PAGE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2020, 72, 847-854.	1.8	49
60	Liver stiffness measurement predicts longã-term survival and complications in nonã-alcoholic fatty liver disease. <i>Liver International</i> , 2020, 40, 581-589.	1.9	75
61	Development of a Novel Inflammation-Based Index for Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2020, 9, 167-181.	4.2	28
62	Reply. <i>Gastroenterology</i> , 2020, 158, 2312-2313.	0.6	2
63	HCC risk reduction with oral nucleos(t)ide analogues in patients with chronic hepatitis B: Not perfect, not good enough. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1661-1662.	1.4	0
64	Pattern and impact of hepatic adverse events encountered during immune checkpoint inhibitors ã A territoryã-wide cohort study. <i>Cancer Medicine</i> , 2020, 9, 7052-7061.	1.3	14
65	Collateral Effect of Coronavirus Disease 2019 Pandemic on Hospitalizations and Clinical Outcomes in Gastrointestinal and Liver Diseases: A Territory-wide Observational Study in Hong Kong. <i>Gastroenterology</i> , 2020, 159, 1979-1981.e3.	0.6	18
66	Differential Impact of Extended Criteria Donors After Brain Death or Circulatory Death in Adult Liver Transplantation. <i>Liver Transplantation</i> , 2020, 26, 1603-1617.	1.3	21
67	Secondary prevention for hepatocellular carcinoma in patients with chronic hepatitis B: are all the nucleos(t)ide analogues the same?. <i>Journal of Gastroenterology</i> , 2020, 55, 1023-1036.	2.3	10
68	Immune checkpoint inhibitors and hepatitis B viral kinetics ã a territory-wide cohort study. <i>Journal of Hepatology</i> , 2020, 73, S68.	1.8	0
69	Increasing antiviral treatment uptake improves survival in patients with HBV-related HCC. <i>JHEP Reports</i> , 2020, 2, 100152.	2.6	18
70	DATA-GRU: Dual-Attention Time-Aware Gated Recurrent Unit for Irregular Multivariate Time Series. <i>Proceedings of the AAAI Conference on Artificial Intelligence</i> , 2020, 34, 930-937.	3.6	48
71	Risk of hepatitis flare in inflammatory bowel disease patients with previous hepatitis B virus exposure - results from a territory-wide Hong Kong ibd registry study. <i>Journal of Hepatology</i> , 2020, 73, S589-S590.	1.8	0
72	Evaluation of page-b and modified page-b scores to guide hepatocellular carcinoma surveillance in chronic hepatitis B patients on antiviral therapy - a territory-wide study of 32,150 subjects. <i>Journal of Hepatology</i> , 2020, 73, S599-S600.	1.8	0

#	ARTICLE	IF	CITATIONS
73	Elevated testosterone increases risk of hepatocellular carcinoma in men with chronic hepatitis B and diabetes mellitus. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 2210-2219.	1.4	19
74	Temporal matrix completion with locally linear latent factors for medical applications. <i>Artificial Intelligence in Medicine</i> , 2020, 107, 101883.	3.8	2
75	Reply to: "Hepatocellular carcinoma risk stratification in HBV cirrhosis: Time to turn the page". <i>Journal of Hepatology</i> , 2020, 73, 729-730.	1.8	0
76	Serum hepatitis B core-related antigen predicts hepatocellular carcinoma in hepatitis B e antigen-negative patients. <i>Journal of Gastroenterology</i> , 2020, 55, 899-908.	2.3	18
77	Assessment of HCC Risk in Patients with Chronic HBV (REACH, PAGE-B, and Beyond). <i>Current Hepatology Reports</i> , 2020, 19, 285-292.	0.4	2
78	Cancer risk and chemoprevention in Chinese inflammatory bowel disease patients: a population-based cohort study. <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 279-286.	0.6	12
79	Letter: is tenofovir superior to entecavir for hepatocellular carcinoma prevention in chronic hepatitis B? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 315-316.	1.9	0
80	Factors associated with improvement in MELD score after antiviral treatment in patients with chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1610-1618.	1.4	4
81	High incidence of hepatocellular carcinoma and cirrhotic complications in patients with psychiatric illness: a territory-wide cohort study. <i>BMC Gastroenterology</i> , 2020, 20, 128.	0.8	6
82	Thiazolidinediones reduce the risk of hepatocellular carcinoma and hepatic events in diabetic patients with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2020, 27, 904-914.	1.0	17
83	Hepatic adverse events during treatment with immune checkpoint inhibitors (ICI) in cancer patients: A territory-wide patient cohort study. <i>Journal of Clinical Oncology</i> , 2020, 38, 508-508.	0.8	0
84	IDDF2020-ABS-0200...Impact of rising prevalence of metabolic comorbidities on accuracy of hepatocellular carcinoma risk score in chronic hepatitis B patients receiving antiviral therapy: A territory-wide cohort of 31,953 treated patients. , 2020, , .		0
85	IDDF2020-ABS-0138...Collateral effect of COVID-19 pandemic on hospitalizations and clinical outcomes in gastrointestinal and liver diseases " a territory-wide observational study in Hong Kong. , 2020, , .		0
86	SAT-142-Incidence of hepatocellular carcinoma and cirrhotic complications in patients with psychiatric illness: A territory-wide cohort study. <i>Journal of Hepatology</i> , 2019, 70, e693.	1.8	0
87	THU-237-Increasing prevalence of indications to choose bone/renal-friendly antiviral drug: A territory-wide study of 135,414 patients from 2000 to 2017. <i>Journal of Hepatology</i> , 2019, 70, e269.	1.8	0
88	Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 1037-1048.	1.9	54
89	Stopping anti-tumour necrosis factor therapy in patients with perianal Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 1195-1203.	1.9	10
90	SAT-288-Liver stiffness measurement predicts long-term survival and complications in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2019, 70, e763-e764.	1.8	4

#	ARTICLE	IF	CITATIONS
91	SAT-147-Interaction between renal and liver impairment on the risk of lactic acidosis in diabetic patients with chronic hepatitis B-related cirrhosis. <i>Journal of Hepatology</i> , 2019, 70, e696.	1.8	0
92	SAT-072-Predict improvement of liver cirrhosis after antiviral treatment in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2019, 70, e659.	1.8	0
93	LBO-03-Tenofovir treatment has lower risk of hepatocellular carcinoma than entecavir treatment in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2019, 70, e128.	1.8	10
94	Improvement in enhanced liver fibrosis score and liver stiffness measurement reflects lower risk of hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1509-1517.	1.9	14
95	Current Knowledge of Occult Hepatitis B Infection and Clinical Implications. <i>Seminars in Liver Disease</i> , 2019, 39, 249-260.	1.8	45
96	Machine learning model to predict recurrent ulcer bleeding in patients with history of idiopathic gastroduodenal ulcer bleeding. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 912-918.	1.9	41
97	IDDF2019-ABS-0199â€¦The risk of metabolic acidosis in diabetic patients with different severity of chronic hepatitis B-related cirrhosis and renal impairment. , 2019, , .		0
98	Impact of dose and duration of corticosteroid on the risk of hepatitis flare in patients with chronic hepatitis B. <i>Liver International</i> , 2019, 39, 271-279.	1.9	23
99	Reply to: â€œDiabetes mellitus as a risk factor of hepatocellular carcinoma in patients with chronic hepatitis B on nucleot(s)ide analoguesâ€. <i>Journal of Hepatology</i> , 2019, 70, 796-797.	1.8	4
100	HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues. <i>Journal of Hepatology</i> , 2019, 70, 361-370.	1.8	173
101	UA-CRNN: Uncertainty-Aware Convolutional Recurrent Neural Network for Mortality Risk Prediction. , 2019, , .		12
102	Effects of Diabetes and Glycemic Control on Risk of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 765-773.e2.	2.4	48
103	Chronic Hepatitis B Increases Liver-Related Mortality of Patients With Acute Hepatitis E: A Territorywide Cohort Study From 2000 to 2016. <i>Clinical Infectious Diseases</i> , 2018, 67, 1278-1284.	2.9	39
104	Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B. <i>Journal of Hepatology</i> , 2018, 69, 278-285.	1.8	120
105	A hidden Markov model for earthquake prediction. <i>Stochastic Environmental Research and Risk Assessment</i> , 2018, 32, 1415-1434.	1.9	15
106	Reply to: â€œRisk factors of hepatocellular carcinoma after hepatitis B surface antigen seroclearanceâ€. <i>Journal of Hepatology</i> , 2018, 68, 208-209.	1.8	0
107	Impact of diabetes mellitus and hepatitis B virus coinfection on patients with chronic hepatitis C: A territorywide cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 934-941.	1.4	10
108	Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue-treated patients. <i>Journal of Hepatology</i> , 2018, 68, 63-72.	1.8	77

#	ARTICLE	IF	CITATIONS
109	IDDF2018-ABS-0058...Early normalisation of alanine aminotransferase (alt) after nucleos(t)ide analogue treatment reduces the risk of hepatocellular carcinoma (hcc) in patients with chronic hepatitis b " a territory-wide study of 21,182 subjects. , 2018, , .		0
110	On-Treatment Improvement of MELD Score Reduces Death and Hepatic Events in Patients With Hepatitis B-Related Cirrhosis. American Journal of Gastroenterology, 2018, 113, 1629-1638.	0.2	24
111	Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B. Journal of Hepatology, 2018, 69, 793-802.	1.8	79
112	Early on-treatment alanine aminotransferase normalization reduces risk of hepatic events in patients with chronic hepatitis B. Journal of Hepatology, 2018, 68, S485.	1.8	0
113	Chronic kidney disease progression in patients with chronic hepatitis B on tenofovir, entecavir, or no treatment. Alimentary Pharmacology and Therapeutics, 2018, 48, 984-992.	1.9	59
114	A Hybrid Residual Network and Long Short-Term Memory Method for Peptic Ulcer Bleeding Mortality Prediction. AMIA ... Annual Symposium proceedings, 2018, 2018, 998-1007.	0.2	4
115	Long-term use of oral nucleos(t)ide analogues for chronic hepatitis B does not increase cancer risk " a cohort study of 44 494 subjects. Alimentary Pharmacology and Therapeutics, 2017, 45, 1213-1224.	1.9	23
116	Laboratory parameter-based machine learning model for excluding non-alcoholic fatty liver disease (<scp>NAFLD</scp>) in the general population. Alimentary Pharmacology and Therapeutics, 2017, 46, 447-456.	1.9	132
117	How to identify patients with advanced liver disease in the community?. Hepatology, 2017, 66, 7-9.	3.6	7
118	Prognostic Value of Controlled Attenuation Parameter by Transient Elastography. American Journal of Gastroenterology, 2017, 112, 1812-1823.	0.2	67
119	Statins reduce the risk of liver decompensation and death in chronic viral hepatitis: a propensity score weighted landmark analysis. Alimentary Pharmacology and Therapeutics, 2017, 46, 1001-1010.	1.9	48
120	Editorial: progress towards a simple tool for screening for hepatic steatosis in the general population " authors' reply. Alimentary Pharmacology and Therapeutics, 2017, 46, 560-561.	1.9	0
121	Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance. Journal of Hepatology, 2017, 67, 902-908.	1.8	112
122	How long will it take to eliminate HCC risk in patients with chronic hepatitis B patients with potent antivirals?. AME Medical Journal, 2017, 2, 141-141.	0.4	1
123	Oral nucleos(t)ide analogues reduce recurrence and death in chronic hepatitis B-related hepatocellular carcinoma. Alimentary Pharmacology and Therapeutics, 2016, 43, 802-813.	1.9	39
124	Long-term safety of oral nucleos(t)ide analogs for patients with chronic hepatitis B: A cohort study of 53,500 subjects. Hepatology, 2015, 62, 684-693.	3.6	77
125	Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population: A propensity score landmark analysis. Journal of Hepatology, 2015, 63, 1190-1197.	1.8	83
126	Statistical strategies for HCC risk prediction models in patients with chronic hepatitis B. Hepatoma Research, 0, 2021, .	0.6	1

#	ARTICLE	IF	CITATIONS
127	Adverse Clinical Outcomes in COVID-19 Versus SARS: A Territory-Wide Cohort Study in Hong Kong. SSRN Electronic Journal, 0, , .	0.4	1
128	Overview of methodologies and statistical strategies in observational studies and meta-analyses on the risk of hepatocellular carcinoma in patients with chronic hepatitis B on entecavir or tenofovir therapy. Hepatoma Research, 0, , .	0.6	1